The prostate stem cell antigen (PSCA) is a notable antigen; owing to its overexpression in prostate cancer, and exclusively in metastatic tissues; thus, it is a promising candidate for prostate cancer immunotherapy (145, 146). This evidence concerns the gene PSCA and prostate carcinoma.